bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have earned an average recommendation of "Hold" from the eleven analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $3.03.

BLUE has been the topic of a number of recent research reports. Barclays cut their target price on bluebird bio from $4.00 to $2.00 and set an "overweight" rating on the stock in a research note on Friday, November 15th. Bank of America cut shares of bluebird bio from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $3.00 to $0.50 in a report on Friday, November 15th. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Wells Fargo & Company cut their target price on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Wednesday, September 25th. Finally, JPMorgan Chase & Co. cut bluebird bio from a "neutral" rating to an "underweight" rating in a research note on Friday, November 15th.

Hedge Funds Weigh In On bluebird bio

Institutional investors have recently made changes to their positions in the business. Allegheny Financial Group LTD purchased a new position in bluebird bio during the second quarter valued at $25,000. Verition Fund Management LLC purchased a new position in shares of bluebird bio during the 3rd quarter valued at about $42,000. Bayesian Capital Management LP bought a new position in shares of bluebird bio during the 1st quarter valued at approximately $52,000. SG Americas Securities LLC increased its holdings in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 74,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in bluebird bio by 113.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 29,113 shares during the period. Institutional investors own 87.43% of the company's stock.

bluebird bio Stock Up 17.5 %

NASDAQ BLUE traded up $0.05 during trading hours on Friday, reaching $0.35. 10,379,941 shares of the company's stock traded hands, compared to its average volume of 5,541,035. bluebird bio has a 52-week low of $0.29 and a 52-week high of $5.53. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The firm has a 50-day simple moving average of $0.46 and a 200 day simple moving average of $0.76. The firm has a market cap of $68.07 million, a PE ratio of -0.19 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE - Get Free Report) last announced its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. The business had revenue of $18.57 million for the quarter. Sell-side analysts anticipate that bluebird bio will post -1.35 EPS for the current fiscal year.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.